Table 1.
Demographic Characteristics of Study Subjects from the Yale Adult Cystic Fibrosis Program and Healthy Control Subjects
| Characteristics | HC Subjects (n = 5) | Subjects with CF (n = 9) |
|---|---|---|
| Age, yr | ||
| Mean ± SD | 35.4 ± 5.9 | 30.6 ± 6.5 |
| Range | 26–42 | 24–43 |
| Sex, n (%) | ||
| F | 2 (40) | 6 (67) |
| M | 3 (60) | 3 (33) |
| Mutation background, n (%) | ||
| F508del/F508del | NA | 7 (77.8) |
| F508del/other | NA | 2 (22.2) |
| No F508del mutations | NA | 0 (0) |
| FEV1, L | ||
| Mean ± SD | NA | 1.9 ± 0.7 |
| Range | NA | 0.68–2.85 |
| FEV1, % | ||
| Mean ± SD | NA | 57 ± 21.5 |
| Range | NA | 19–84 |
| BMI, kg/m2 | ||
| Mean ± SD | NA | 22.2 ± 2.1 |
| Range | NA | 19.11–25.73 |
| CF comorbidities, n (%) | ||
| Pancreatic exocrine insufficiency | NA | 9 (100) |
| CF-related diabetes | NA | 4 (44.4) |
| Liver disease | NA | 1 (11.1) |
| Microbiology, n (%) | ||
| P. aeruginosa colonization | NA | 5 (55.6) |
| CFTR modulators, n (%) | ||
| Ivacaftor/tezacaftor | NA | 6 (66.7) |
| Ivacaftor/lumacaftor | NA | 2 (22.2) |
| No modulator | NA | 1 (11.1) |
Definition of abbreviations: BMI = body mass index; CF = cystic fibrosis; CFTR= cystic fibrosis transmembrane conductance regulator; HC = healthy control; NA = not applicable; P. aeruginosa = Pseudomonas aeruginosa.